MA30565B1 - Procede de diagnostic et traitement anticancereux - Google Patents

Procede de diagnostic et traitement anticancereux

Info

Publication number
MA30565B1
MA30565B1 MA31490A MA31490A MA30565B1 MA 30565 B1 MA30565 B1 MA 30565B1 MA 31490 A MA31490 A MA 31490A MA 31490 A MA31490 A MA 31490A MA 30565 B1 MA30565 B1 MA 30565B1
Authority
MA
Morocco
Prior art keywords
diagnostic method
anticancer treatment
mage
gene
specific
Prior art date
Application number
MA31490A
Other languages
English (en)
French (fr)
Inventor
Thierry Coche
Olivier Gruselle
Gabriele Anne-Marie Beer
Dennis Salonga
Craig Lawrence Stephens
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA30565B1 publication Critical patent/MA30565B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091Purification or manufacturing processes for gene therapy compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6841In situ hybridisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Manufacturing & Machinery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MA31490A 2006-06-21 2008-12-19 Procede de diagnostic et traitement anticancereux MA30565B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612342.6A GB0612342D0 (en) 2006-06-21 2006-06-21 Method

Publications (1)

Publication Number Publication Date
MA30565B1 true MA30565B1 (fr) 2009-07-01

Family

ID=36803668

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31490A MA30565B1 (fr) 2006-06-21 2008-12-19 Procede de diagnostic et traitement anticancereux

Country Status (27)

Country Link
US (1) US8936919B2 (https=)
EP (1) EP2041308B1 (https=)
JP (2) JP2009540812A (https=)
KR (1) KR101455589B1 (https=)
CN (1) CN101506383B (https=)
AU (1) AU2007263019B2 (https=)
BR (1) BRPI0713599A2 (https=)
CA (1) CA2656909A1 (https=)
CO (1) CO6140072A2 (https=)
CY (1) CY1113290T1 (https=)
DK (1) DK2041308T3 (https=)
EA (1) EA016347B1 (https=)
ES (1) ES2389513T3 (https=)
GB (1) GB0612342D0 (https=)
HR (1) HRP20120761T1 (https=)
IL (1) IL195975A (https=)
MA (1) MA30565B1 (https=)
MX (1) MX2008016493A (https=)
MY (1) MY147511A (https=)
NO (1) NO20085290L (https=)
NZ (1) NZ573809A (https=)
PL (1) PL2041308T3 (https=)
PT (1) PT2041308E (https=)
SI (1) SI2041308T1 (https=)
UA (1) UA95956C2 (https=)
WO (1) WO2007147876A2 (https=)
ZA (1) ZA200810695B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2699853A1 (en) 2007-09-17 2009-03-26 Oncomethylome Sciences Sa Improved detection of mage-a expression
BR112013001637A2 (pt) * 2010-07-22 2016-05-24 Glaxosmithkline Biolog Sa proteína ligadora de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, métodos para produção de proteína ligadora de antígeno, e para detectar mage-a3 e/ou mage-a6 em tecido de humano fixado com formalina e infiltrado em parafina.
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612201A (en) * 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
AU4998993A (en) * 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
WO1995023874A1 (en) * 1994-03-01 1995-09-08 Ludwig Institute For Cancer Research Determination of cancerous conditions by mage gene expression
US5985571A (en) * 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
PT1053325E (pt) * 1998-02-05 2006-05-31 Glaxosmithkline Biolog Sa Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao.
WO2000020445A2 (en) * 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
JP3603138B2 (ja) * 2000-02-18 2004-12-22 独立行政法人理化学研究所 細胞死抑制タンパク質
US6358679B1 (en) * 2000-08-24 2002-03-19 Pe Corporation (Ny) Methods for external controls for nucleic acid amplification
US6635425B2 (en) 2001-01-05 2003-10-21 Molecular Staging, Inc. 5′-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms
RU2313365C2 (ru) 2001-11-29 2007-12-27 Дандрит Байотек А/С Фармацевтическая композиция для индукции иммунной реакции у человека
EP2363500A1 (en) * 2002-11-14 2011-09-07 John Wayne Cancer Institute Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimaker quantitative RT-PCR
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer

Also Published As

Publication number Publication date
JP2009540812A (ja) 2009-11-26
DK2041308T3 (da) 2012-10-08
EA200802356A1 (ru) 2009-06-30
CO6140072A2 (es) 2010-03-19
JP2013046630A (ja) 2013-03-07
PL2041308T3 (pl) 2012-11-30
JP5705191B2 (ja) 2015-04-22
IL195975A0 (en) 2009-09-01
MY147511A (en) 2012-12-31
HK1127627A1 (en) 2009-10-02
NO20085290L (no) 2009-01-19
EP2041308B1 (en) 2012-07-11
CY1113290T1 (el) 2016-04-13
US8936919B2 (en) 2015-01-20
AU2007263019B2 (en) 2012-11-08
IL195975A (en) 2012-08-30
HRP20120761T1 (hr) 2012-10-31
NZ573809A (en) 2011-12-22
MX2008016493A (es) 2009-05-21
GB0612342D0 (en) 2006-08-02
BRPI0713599A2 (pt) 2012-11-06
US20120040341A1 (en) 2012-02-16
AU2007263019A1 (en) 2007-12-27
CN101506383B (zh) 2013-08-28
KR20090034900A (ko) 2009-04-08
CA2656909A1 (en) 2007-12-27
EA016347B1 (ru) 2012-04-30
KR101455589B1 (ko) 2014-10-28
ZA200810695B (en) 2014-03-26
WO2007147876A3 (en) 2008-05-15
UA95956C2 (uk) 2011-09-26
CN101506383A (zh) 2009-08-12
EP2041308A2 (en) 2009-04-01
SI2041308T1 (sl) 2012-10-30
ES2389513T3 (es) 2012-10-26
WO2007147876A2 (en) 2007-12-27
PT2041308E (pt) 2012-10-09

Similar Documents

Publication Publication Date Title
Buddingh et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents
Daurkin et al. Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway
CA2900022C (en) Non-invasive diagnostic method for diagnosing bladder cancer
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
EP1937280A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND THERAPY OF BCL2 ASSOCIATED TUMORS
US20210380712A1 (en) Targeting metastasis stem cells through a fatty acid receptor (cd36)
MA33747B1 (fr) Anticorps monoclonaux diriges contre la progastrine et leurs utilisations
EP1937845A4 (en) MICRO-RNA-BASED METHOD AND COMPOSITIONS FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF BREAST CANCER
EP2302079A3 (en) Systemic lupus erythematosus diagnostic assay
Sharif-Zak et al. CCR2 and DPP9 expression in the peripheral blood of COVID-19 patients: Influences of the disease severity and gender
MA30393B1 (fr) Procede de traitement, de diagnostic ou de detection du cancer
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
HU0400904D0 (en) Use of genes as molecular markers in diagnosis of schizophrenia and diagnostic kit for the same
EP2367939A4 (en) METHOD FOR DIAGNOSIS OR TREATMENT OF PROSTATE CANCER
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
MX2009001937A (es) Biomarcadores para el progreso de la enfermedad de alzheimer.
MA30565B1 (fr) Procede de diagnostic et traitement anticancereux
EP1987165A4 (en) Gene with influence on the human memory
Elhelbawy et al. Immunological microenvironment gene expression in patients with diffuse large B cell non Hodgkin lymphoma
ATE461294T1 (de) Brustkrebsdiagnoseverfahren
Althubiti β2-microglobulin is overexpressed in buccal cells of elderly and correlated with expression of p16 and inflammatory genes
JP6397765B2 (ja) プロテアソーム阻害剤に応答するバイオマーカー
CN108450004A (zh) 通过调节RhoH来鉴定新的诊断和治疗